Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)

NCT01482143 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
21
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals